Proposed Secondary Placing of Ordinary Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Clinigen Group plc

30 September 2013

PROPOSED SECONDARY PLACING OF ORDINARY SHARES IN CLINIGEN GROUP PLC

Burton-on-Trent, UK - 30 September 2013 - Clinigen Group plc ("Clinigen" or the "Company", AIM: CLIN), the global specialty pharmaceuticals and services company, today announces that it has been advised by Numis Securities Limited ("Numis") acting as bookrunner and joint broker and Peel Hunt LLP ("Peel Hunt") acting as joint broker that, as instructed by several Directors and employees of Clinigen set out below ("the Vendors"), Numis and Peel Hunt intend to sell up to 8,723,826 existing ordinary shares of 0.1p each in the Company ("the Placing Shares") on behalf of the Vendors via an accelerated bookbuild placing ("the Placing"). The Placing Shares represent in aggregate approximately 10.6 per cent of the 82,555,585 ordinary shares which comprise the issued share capital of Clinigen.

Details of the maximum numbers of Placing Shares to be disposed of by the Vendors are as follows:

The Placing will be managed by Numis acting as bookrunner (the "Bookrunner") with Peel Hunt acting as joint broker. The number of Placing Shares and the Placing price will be decided at the close of the accelerated bookbuilding period.

The books for the Placing will open with immediate effect. Pricing is expected to be announced as soon as practicable following the closing of the books. The timing of closing of the books will be at the absolute discretion of the Bookrunner in consultation with Peel Hunt.

- Ends -

 Enquiries:

Numis and Peel Hunt are acting exclusively for the Vendors in relation to the Placing and will not be responsible to anyone other than the Vendors for providing the protections afforded to their clients, nor for providing advice in relation to the Placing, the contents of this announcement, or any transaction or arrangement referred to herein.

This announcement is for information purposes only and does not constitute or form part of an offer or invitation to acquire or dispose of any securities in Clinigen, or constitute a solicitation of any offer to purchase or subscribe for securities in any jurisdiction, including the United States, Canada, Australia or Japan. Clinigen's shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or under the securities legislation of any state of the United States and may not be offered or sold in the United States absent registration or an exemption from registration.

This announcement is not for publication or distribution to persons in the United States of America, its territories or possessions or to any US person (within the meaning of Regulation S under the US Securities Act of 1933, as amended). Neither this announcement nor any copy of it may be taken or transmitted into Australia, Canada or Japan or to Canadian persons or to any securities analyst or other person in any of those jurisdictions. Any failure to comply with this restriction may constitute a violation of United States, Australian, Canadian or Japanese securities law. The distribution of this announcement in certain other jurisdictions may be restricted by law and persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions.

This announcement and any offer of securities to which it relates are only addressed to and directed at persons who are (1) qualified investors within the meaning of directive 2003/71/ec and any relevant implementing measures (the prospectus directive) and (2) who have professional experience in matters relating to investments and who fall within article 19(1) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or are persons falling within article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order (all such persons together being referred to as "relevant persons"). The information regarding the Placing set out in this announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.